TV‐1106 is a human serum albumin genetically fused to recombinant human growth
hormone, designed to provide a long‐acting alternative to daily growth hormone (GH) …

Daily injections of growth hormone (GH) as replacement therapy in GH‐deficient (GHD)
patients may cause poor compliance and inconvenience. C‐terminal peptide–modified …

Background: Administration of daily recombinant human GH (rhGH) poses a considerable
challenge to patient compliance. Reduced dosing frequency may improve treatment …

Context: LB03002 is a novel sustained-release GH preparation administered once weekly.
Objective: Our objective was to examine the pharmacokinetics, pharmacodynamics, and …

Abstract Background TV-1106 (Teva Pharmaceuticals) is a genetically fused recombinant
protein of human GH (hGH) and human serum albumin, in development for treatment of GH …

Context: Human growth hormone (hGH) replacement therapy currently requires daily sc
injections for years/lifetime, which may be both inconvenient and distressing for patients …

Background: A sustained-release recombinant human GH formulation, LB03002, has been
recently developed, with pharmacokinetics and pharmacodynamic activity appropriate for …

Objective Growth hormone (GH) replacement therapy currently requires daily injections,
which may cause distress and low compliance. C-terminal peptide (CTP)-modified growth …

Abstract Context: NNC0195-0092 is a reversible, albumin-binding GH derivative, developed
for once-weekly administration. Objectives: The objective of the study was to evaluate safety …

MOD-4023 is a novel long-acting version of human growth hormone (hGH), containing the
carboxy-terminal peptide (CTP) of human chorionic gonadotropin (hCG). MOD-4023 is …